Paul Turner on the Next Decade of Phage Therapy: Clinical Trials, Engineered Phages and Global Access
Phage therapy is entering a period in which the central questions are no longer limited to whether bacteriophages can kill antibiotic-resistant bacteria. The field is increasingly confronting harder translational questions: which phages should be used, whether natural isolates or engineered viruses will ultimately dominate, how safety should be assessed, how clinical efficacy can be demonstrated, and how phage therapy can become accessible beyond a small number of specialist centers. Source : https://encrypted-tbn0.gstatic.com/images?q=tbn:ANd9GcTZ0kF9EL6WWX6Rr3fwUt2-v_9i2q3bmFQmoIlaWlW8Zh-KoefWs18muoo&s=10 In a new episode of New England Biolabs’ Lessons from Lab & Life podcast, Paul Turner, Rachel Carson Professor of Ecology and Evolutionary Biology at Yale University and a faculty member at Yale School of Medicine, discusses where he thinks the field is heading over the next five to ten years. Turner studies the evolutionary genetics of viruses and has become a major f...